The primary safety concern for biosimilar agents is their potential immunogenicity. Using biopharmaceuticals to replace endogenous proteins that may be present at insufficient concentrations carries the serious risk of stimulating the immune system to develop anti-product antibodies (Abs), which may cross-react with endogenous protein.
- INICIO
-
Genéricos
Novedades
- Five Chinese companies join UN’s MPP for Covid-19 medicines
- South Korean companies to make generic Bridion and COVID-19 drugs
- Revlimid (lenalidomide) generics launch across Europe
- Cancer and diabetes generic treatments receive positive opinion from EMA’s CHMP
Investigación
- The cost of developing drugs and use of generics
- Re-evaluation of the use of generics, especially when treating conditions such as epilepsy
- La reutilización de medicamentos genéricos puede ahorrar tiempo y dinero
- Availability of medicines and the sustainable development of the national health system in Russia
-
Biosimilares
Novedades
- Lucentis biosimilars approved in the UK and Korea
- Nuevos biosimilares de adalimumab se preparan para su lanzamiento en Canadá, EE.UU. y Europa
- FDA approves Amneal’s bevacizumab biosimilar
- Europe: positive opinion for Inpremzia and Truvelog Mix 30 and Stimufend authorized
Investigación
- Patient perspectives on biosimilars in a high uptake country
- Biosimilar adoption and prescribing in Japan: a physician opinion survey
- Innovent and Eli Lilly announce final results for sintilimab plus biosimilar bevacizumab injection
- Totality of evidence supporting approval of Avsola in the treatment of IBD
- MORE EDITORIAL SECTIONS
- Search
Post your comment